Free Trial

Moderna (MRNA) Stock Forecast & Price Target

Moderna logo
$36.86 -0.08 (-0.22%)
(As of 12:30 PM ET)

Moderna - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
3
Hold
13
Buy
6

Based on 22 Wall Street analysts who have issued ratings for Moderna in the last 12 months, the stock has a consensus rating of "Hold." Out of the 22 analysts, 3 have given a sell rating, 13 have given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for MRNA.

Consensus Price Target

$84.00
127.89% Upside
According to the 22 analysts' twelve-month price targets for Moderna, the average price target is $84.00. The highest price target for MRNA is $179.00, while the lowest price target for MRNA is $40.00. The average price target represents a forecasted upside of 127.89% from the current price of $36.86.
Get the Latest News and Ratings for MRNA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Moderna and its competitors.

Sign Up

MRNA Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
4 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
Hold
13 Hold rating(s)
14 Hold rating(s)
8 Hold rating(s)
9 Hold rating(s)
Sell
3 Sell rating(s)
2 Sell rating(s)
1 Sell rating(s)
3 Sell rating(s)
Consensus Price Target$84.00$97.18$124.07$143.02
Forecasted Upside127.89% Upside81.98% Upside50.50% Upside82.96% Upside
Consensus Rating
Hold
Hold
Hold
Hold

MRNA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MRNA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Moderna Stock vs. The Competition

TypeModernaMedical CompaniesS&P 500
Consensus Rating Score
2.18
2.80
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside127.40% Upside26,931.53% Upside9.83% Upside
News Sentiment Rating
Positive News

See Recent MRNA News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/19/2024Berenberg Bank
2 of 5 stars
H. Gillis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$42.00+6.30%
11/18/2024Hsbc Global Res
0 of 5 stars
Y. Liu
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
11/18/2024Piper Sandler
2 of 5 stars
 Reiterated RatingOverweight ➝ Overweight$115.00 ➝ $69.00+76.83%
11/18/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$58.00+57.39%
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Hammond
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageUnderperform$40.00+0.58%
11/8/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$125.00 ➝ $111.00+134.08%
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)

The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…

11/8/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
11/4/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderweight ➝ Underweight$70.00 ➝ $59.00+8.66%
10/24/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$140.00 ➝ $108.00+104.55%
10/17/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Breen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$55.00-4.28%
10/15/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$65.00 ➝ $55.00-4.75%
9/19/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Issi
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$75.00 ➝ $75.00+6.47%
9/17/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderperform ➝ Underperform$60.00 ➝ $48.00-34.09%
9/16/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$178.00 ➝ $139.00+101.19%
9/13/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$130.00 ➝ $110.00+62.87%
9/13/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$70.00 ➝ $60.00-9.92%
9/13/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
8/7/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSell ➝ Hold$85.00 ➝ $80.00-2.79%
6/27/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMarket Perform
6/27/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Kasimov
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingIn-Line ➝ In-Line$120.00 ➝ $120.00-2.00%
5/3/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$91.00 ➝ $106.00-15.20%
9/13/2023Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$160.00 ➝ $140.00+26.96%
8/4/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$128.00 ➝ $123.00+13.37%
6/26/202351job
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingUpgrade
4/25/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral
2/24/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeMarket Perform ➝ Underperform$111.00 ➝ $93.00-36.98%
1/25/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform$130.00 ➝ $150.00-23.76%
1/18/2023Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Y. Livshits
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral$191.00 ➝ $208.00+4.17%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:49 PM ET.


Should I Buy Moderna Stock? MRNA Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, November 8, 2024. Please send any questions or comments about these Moderna pros and cons to contact@marketbeat.com.

Moderna
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Moderna, Inc.:

  • Moderna's stock price has shown resilience despite recent market fluctuations, indicating strong investor confidence.
  • Recent analyst reports have highlighted Moderna as a potential buy opportunity, with price targets suggesting room for growth.
  • Moderna's innovative mRNA technology has positioned the company as a leader in the development of cutting-edge vaccines and therapeutics.
  • Insider selling of shares by company executives may not necessarily indicate negative sentiment, as it could be part of a pre-planned strategy or profit-taking.
  • Moderna's consistent focus on research and development, especially in the field of mRNA-based treatments, offers long-term growth potential.

Moderna
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Moderna, Inc. for these reasons:

  • Moderna's stock has experienced volatility, which may pose risks for short-term investors seeking stable returns.
  • The company's high debt-to-equity ratio could indicate financial leverage concerns, impacting its ability to weather economic downturns.
  • Recent insider selling activities, especially by key executives, may raise questions about the company's future performance and growth prospects.
  • Analysts have issued mixed ratings on Moderna, with some suggesting caution due to uncertainties in the biotech industry and regulatory challenges.
  • Market competition and potential disruptions in the healthcare sector could impact Moderna's market share and revenue growth in the future.

MRNA Forecast - Frequently Asked Questions

According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Moderna is $84.00, with a high forecast of $179.00 and a low forecast of $40.00.

22 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last twelve months. There are currently 3 sell ratings, 13 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.

According to analysts, Moderna's stock has a predicted upside of 127.89% based on their 12-month stock forecasts.

Over the previous 90 days, Moderna's stock had 4 upgrades and 3 downgrades by analysts.

Analysts like Moderna less than other "medical" companies. The consensus rating for Moderna is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MRNA compares to other companies.


This page (NASDAQ:MRNA) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners